Chemotherapy for brain metastases of lung cancer: A review

被引:70
作者
Postmus, PE [1 ]
Smit, EF [1 ]
机构
[1] Vrije Univ Amsterdam, Univ Hosp, Dept Pulm Dis, NL-1007 MB Amsterdam, Netherlands
关键词
chemotherapy; brain metastases; lung cancer;
D O I
10.1023/A:1008318515795
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In lung cancer patients brain metastases develop with a high frequency. For years radiotherapy has been the standard treatment for these patients. Here we review the experience with chemotherapy for brain metastases in lung cancer patients. The concept of the brain as pharmacological sanctuary site when brain metastases are present is challenged and it is argued that chemotherapy does play a role in this situation. Recent clinical trials indicate that the combination of chemotherapy and radiotherapy may become the standard treatment for lung cancer patients with brain metastases. It is unclear whether for micrometastatic disease to the brain, blood brain barrier function is of importance for the outcome of chemotherapy in lung cancer patients with respect to the development of overt brain metastases. Areas of improvement of delivery of cytotoxic agents to the brain when brain metastases have not yet developed are discussed.
引用
收藏
页码:753 / 759
页数:7
相关论文
共 88 条
[1]  
ALBERTI W, 1995, BRIT MED J, V311, P899
[2]   Acceptability of patients with brain metastases for clinical trials of chemotherapy for metastatic non-small-cell lung cancer [J].
Ando, Y ;
Sugiura, S ;
Ando, M ;
Minami, H ;
Nomura, F ;
Sakai, S ;
Shimokata, K .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1996, 19 (05) :478-482
[3]   Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease [J].
Ardizzoni, A ;
Hansen, H ;
Dombernowsky, P ;
Gamucci, T ;
Kaplan, S ;
Postmus, P ;
Giaccone, G ;
Schaefer, B ;
Wanders, J ;
Verweij, J .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) :2090-2096
[4]   SEVERE ACUTE ENCEPHALOPATHY FOLLOWING INADVERTENT INTRATHECAL DOXORUBICIN ADMINISTRATION [J].
ARICO, M ;
NESPOLI, L ;
PORTA, F ;
CASELLI, D ;
RAITERI, E ;
BURGIO, GR .
MEDICAL AND PEDIATRIC ONCOLOGY, 1990, 18 (03) :261-263
[5]  
ARONEY RS, 1983, CANCER TREAT REP, V67, P675
[6]  
ARRIAGADA R, 1998, P AN M AM SOC CLIN, V17, pA457
[7]   Brain relapses in chemotherapy-treated small cell lung cancer: A retrospective review of two time-dose regimens of therapeutic brain irradiation [J].
Bach, F ;
Sorensen, JB ;
Adrian, L ;
Larsen, H ;
Langer, SW ;
Nelausen, KM ;
Engelholm, SA .
LUNG CANCER, 1996, 15 (02) :171-181
[8]   NEUROLOGICAL SYMPTOMS AND COMA ASSOCIATED WITH DOXORUBICIN ADMINISTRATION DURING CHRONIC CYCLOSPORINE THERAPY [J].
BARBUI, T ;
RAMBALDI, A ;
PARENZAN, L ;
ZUCCHELLI, M ;
PERICO, N ;
REMUZZI, G .
LANCET, 1992, 339 (8806) :1421-1421
[9]   NEUROLOGICAL SYMPTOMS ASSOCIATED WITH CYCLOSPORINE PLUS DOXORUBICIN [J].
BECK, WT ;
KUTTESCH, JF .
LANCET, 1992, 340 (8817) :496-496
[10]  
BIESMA B, 1997, DRUG RESISTANCE ONCO, P1